Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW conjugate vaccine in adults 56+
NCT02842866Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2016
- Primary completion
- Feb 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of Meningococcal ACWY conjugate vaccine in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants With Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W at Day 30. Started Jul 2016; status: completed.
02
Drugs
Meningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT02842866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842866.